Teva's 2013 outlook misses estimates
Nov 30 (Reuters) - Teva Pharmaceutical Industries Ltd , the world's biggest generic drugmaker, forecast profit and revenue for the calendar 2013 that fell short of analysts' estimates.
The Israel-based company, which posted a quarterly profit above market estimates earlier this month on strong U.S. revenue, expects an adjusted profit of $4.85 to $5.15 per share in 2013 on revenue of $19.5 billion to $20.5 billion.
Analysts were expecting earnings of $5.71 per share, on revenue of $20.85 billion, according to Thomson Reuters I/B/E/S.
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- U.S. court rulings create new uncertainty over Obamacare
- Israel pounds Gaza despite international peace efforts |
- EU readies possible capital, tech sanctions on Russia
- Islamic State crushes and coerces on march towards Baghdad